Skip to main content

Table 1 BRAF status of CTCs detected in MMbraf5 during treatment with dabrafenib and trametinib

From: Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BRAF mutation status of CTC

Day − 60

Day 8

Day 15

Day 36

Day 57

Day 92

Day 120

Day 148

Treatment suspended

Wild type

34

9

14

15

14

6

3

8

17

V600E

9

2

2

1

1

0

0

0

6

V600R

0

1

5

2

1

0

0

0

0

V600M

0

0

0

1

0

0

0

0

0

V600A

0

1

0

0

0

0

0

0

0

K601E

4

2

0

1

1

1

0

0

0

K601R

1

0

0

0

0

0

0

0

0

A598V

0

2

0

0

1

0

1

3

0

The number of isolated CTC

48

17

21

20

18

7

4

11

23

  1. Day, day before or after treatment started
  2. We did not analyze BRAF genotyp of all isolated CTC at each time point